Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases

Research output: Contribution to journalReview article

14 Scopus citations

Abstract

Bile acids are central signals in enterohepatic communication and also integrate microbiota-derived signals into this signaling axis. Discovery of the tissue distribution and signaling pathways activated by the natural receptors for bile acids, farnesoid X receptor and G protein-coupled bile acid receptor 1 (GPBAR1) also known as TGR5, and bile acid transporters has led to the development of therapeutic agents that target these molecules. Obeticholic acid, a selective FXR agonist, and NGM282, a non-mitogenic FGF-19 analog, are two of the agents in this pipeline. Obeticholic acid has been approved by regulatory agencies for use in patients with primary biliary cholangitis.

Original languageEnglish (US)
Pages (from-to)80-86
Number of pages7
JournalCurrent Opinion in Pharmacology
Volume37
DOIs
StatePublished - Dec 2017

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases'. Together they form a unique fingerprint.

  • Cite this